II. Epidemiology
- Responsible for 20-50% of Hypercoagulable patients
-
Incidence of Autosomal Dominant genetic defect
- Europeans: 15%
- North America: 3-5%
III. Risks
- Heterozygote: 5-10 times the risk of thrombosis
- Homozygote: 50-100 times the risk of thrombosis
IV. Pathophysiology
V. Labs
- Activated Protein C (APC) resistance
- Can not be anticoagulated when this lab run
- PCR for Factor V Leiden
- Responsible for 95% of APC Resistance
- Does NOT require that patient be off Anticoagulation